IHH net income down 51% YoY in Q2

The decline was driven by foreign exchange losses amidst Turkish Lira devaluation.

SGX-listed firm IHH Healthcare reported a net income of $88m (RM301.8m), 51% lower year-on-year in the second quarter (Q2) in 2023 from Q2 2022.

It was driven by foreign exchange losses following the Turkish Lira’s devaluation in June 2023.

The group revenue grew 7% YoY, with more patients coming in and higher revenue intensity across markets. EBITDA also grew 3% mainly on the higher revenue.

The net operating income, which reflects the Group’s core performance, was steady, declining 1% on higher net finance costs.

In the first half of 2023, the revenue and EBITDA also posted growth with 15% and 9%, respectively.

The Board of Directors have declared an interim cash dividend of 3.5 sen per ordinary share for the financial year ending 31 December 2023 to be paid on 27 October 2023 to shareholders.

Follow the link for more news on

IHH Healthcare

Financial Statements

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia